Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience

Mutations in DNMT3A encoding DNA methyltransferase 3A were recently described in patients with acute myeloid leukemia. To assess their prognostic significance, we determined the mutational status of DNMT3A exon 23 in 288 patients with AML excluding acute promyelocytic leukemia, aged from 18 to 65 ye...

Descripción completa

Detalles Bibliográficos
Autores principales: LaRochelle, Olivier, Bertoli, Sarah, Vergez, François, Sarry, Jean-Emmanuel, Mansat-De Mas, Véronique, Dobbelstein, Sophie, Dastugue, Nicole, Strzelecki, Anne-Claire, Cavelier, Cindy, Creancier, Laurent, Pillon, Arnaud, Kruczynski, Anna, Demur, Cécile, Sarry, Audrey, Huguet, Françoise, Huynh, Anne, Récher, Christian, Delabesse, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2011
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260002/
https://www.ncbi.nlm.nih.gov/pubmed/22081665

Ejemplares similares

Ejemplares similares